Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
PYXS

PYXS - Pyxis Oncology, Inc. Stock Price, Fair Value and News

3.12USD+0.15 (+5.05%)Market Closed

Market Summary

PYXS
USD3.12+0.15
Market Closed
5.05%

PYXS Stock Price

View Fullscreen

PYXS RSI Chart

PYXS Valuation

Market Cap

174.9M

Price/Earnings (Trailing)

-3.03

Price/Sales (Trailing)

8.28

Price/Free Cashflow

-2.61

PYXS Price/Sales (Trailing)

PYXS Profitability

Return on Equity

-31.39%

Return on Assets

-26.25%

Free Cashflow Yield

-38.39%

PYXS Fundamentals

PYXS Revenue

Revenue (TTM)

21.1M

Rev. Growth (Yr)

865.09%

Rev. Growth (Qtr)

912.92%

PYXS Earnings

Earnings (TTM)

-57.8M

Earnings Growth (Yr)

83.08%

Earnings Growth (Qtr)

79.12%

Breaking Down PYXS Revenue

Last 7 days

2.4%

Last 30 days

-24.7%

Last 90 days

-40.0%

Trailing 12 Months

7.3%

How does PYXS drawdown profile look like?

PYXS Financial Health

Current Ratio

12.19

PYXS Investor Care

Shares Dilution (1Y)

53.98%

Diluted EPS (TTM)

-1.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202421.1M000
20234.4M06.0M6.8M
20221.0M01.9M2.8M
2021000181.0K

Tracking the Latest Insider Buys and Sells of Pyxis Oncology, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 07, 2024
palani santhosh
acquired
-
-
6,000
-
Mar 26, 2024
wadhane jitendra
acquired
-
-
131,484
svp, chief accounting officer
Mar 26, 2024
connealy pamela ann
acquired
-
-
328,710
cfo & coo
Mar 26, 2024
cline darren s
acquired
-
-
35,219
-
Mar 26, 2024
humphrey rachel
acquired
-
-
38,741
-
Mar 26, 2024
dupont jakob
acquired
-
-
38,741
-
Mar 26, 2024
lewis-hall freda c
acquired
-
-
35,219
-
Mar 26, 2024
flavin john l
acquired
-
-
35,219
-
Nov 29, 2023
connealy pamela ann
sold (taxes)
-51,728
1.4
-36,949
cfo and coo
Nov 15, 2023
wadhane jitendra
acquired
-
-
40,000
chief accounting officer

1–10 of 50

Which funds bought or sold PYXS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
Cetera Investment Advisers
added
44.19
88,422
125,074
-%
May 17, 2024
Ikarian Capital, LLC
new
-
7,081,860
7,081,860
0.78%
May 16, 2024
JANE STREET GROUP, LLC
added
1,067
719,544
746,573
-%
May 15, 2024
MARSHALL WACE, LLP
new
-
569,033
569,033
-%
May 15, 2024
Man Group plc
new
-
626,987
626,987
-%
May 15, 2024
Laurion Capital Management LP
added
21.77
10,741,200
16,448,600
0.14%
May 15, 2024
TWO SIGMA ADVISERS, LP
reduced
-75.7
-49,104
66,456
-%
May 15, 2024
Brevan Howard Capital Management LP
new
-
153,305
153,305
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
72.12
31,198
41,348
-%
May 15, 2024
Cetera Advisors LLC
new
-
100,110
100,110
-%

1–10 of 46

Are Funds Buying or Selling PYXS?

Are funds buying PYXS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PYXS
No. of Funds

Unveiling Pyxis Oncology, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 03, 2024
sullivan lara
8.89%
5,489,699
SC 13D/A
Mar 08, 2024
deep track capital, lp
7.87%
4,184,100
SC 13G
Feb 14, 2024
biotechnology value fund l p
-
0
SC 13G/A
Feb 14, 2024
tang capital partners lp
0.0%
0
SC 13G/A
Jan 26, 2024
ridgeback capital investments l.p.
9.8%
4,345,228
SC 13G
Apr 04, 2023
sullivan lara
10.2%
4,170,274
SC 13D/A
Mar 23, 2023
pfizer inc
2.92%
0
SC 13G/A
Feb 14, 2023
rtw investments, lp
0%
0
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
4.5%
1,585,000
SC 13G/A
Feb 14, 2023
ra capital management, l.p.
0%
0
SC 13G/A

Recent SEC filings of Pyxis Oncology, Inc.

View All Filings
Date Filed Form Type Document
Jun 12, 2024
8-K
Current Report
Jun 10, 2024
8-K
Current Report
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
3
Insider Trading
Jun 07, 2024
4
Insider Trading
May 14, 2024
8-K
Current Report
May 14, 2024
10-Q
Quarterly Report
Apr 26, 2024
DEFA14A
DEFA14A
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
ARS
ARS

Peers (Alternatives to Pyxis Oncology, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-17.23% -2.46%
-7.8
6.8
-64.45% -224.75%
33.0B
2.0B
67.01% 29.40%
-99.43
16.48
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.9B
2.5B
0.02% -1.58%
77.55
6.45
13.74% 186.89%
14.0B
3.8B
4.74% -0.56%
18.76
3.71
8.58% 129.81%
MID-CAP
5.0B
107.9M
-2.22% 48.86%
-9.2
48.09
54.84% -28.31%
4.7B
524.1M
-9.01% -54.24%
-11.31
9.01
394.93% 39.61%
4.0B
251.0M
18.93% 13.89%
-13.55
16
73.58% -86.73%
3.5B
240.7M
14.65% -16.72%
-7.42
12.77
-1.03% -213.92%
2.9B
813.8M
17.43% -31.75%
-1.7K
3.58
56.43% 98.83%
1.8B
996.6M
-22.65% 38.54%
-4.61
1.85
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
4.82% 27.42%
30.04
4.76
60.38% -34.49%
628.3M
881.7K
6.14% 580.25%
-18.61
481.06
-77.61% 33.36%
293.1M
4.2M
13.80% 73.74%
-2.35
70.45
-66.30% 48.24%
21.0M
2.1M
-12.55% 263.94%
-0.91
7.61
-13.45% 69.54%

Pyxis Oncology, Inc. News

Latest updates
GlobeNewswire28 Jun 202408:32 pm

Pyxis Oncology, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q12022Q42022Q32022Q12021Q42021Q32021Q2
Revenue912.9%16,1461,5941,7071,6731,872719585450316181
Operating Expenses-100.0%-25,13625,3546,21649,12128,3939,094-24,33411,6215,941
  S&GA Expenses33.9%8,2476,16010,6679,0538,1199,3591,986-2,1703,7722,736
  R&D Expenses12.3%13,02911,60714,68711,90136,33619,0347,108-22,1647,8493,205
Income Taxes----20.00------
Net Income79.1%-3,256-15,597-23,049-19,243-36,101-27,674-31,38030,230-14,175-8,146
Net Income Margin74.6%-2.74*-10.78*-15.79*-24.86*-43.67*-28.58*-22.52*-159.76*--
Free Cashflow-37.3%-20,947-15,254-17,644-6,762-19,245-24,823-8,383-259-7,2882,491
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32020Q4
Assets26.8%22017418717518.0021122424325339.0013910.00
  Current Assets38.3%17212513914917.0018720322725138.001348.00
    Cash Equivalents189.4%28.0010.0015.0026.0053.0017919922324723.001338.00
  Net PPE-4.5%11.0012.0012.0013.00-11.006.001.001.000.001.001.00
Liabilities-24.9%36.0048.0049.0030.0014.0051.0035.0031.0019.0017.0017.004.00
  Current Liabilities-45.1%14.0026.0028.009.0014.0032.0019.0015.0019.0017.0017.004.00
Shareholder's Equity46.5%184126138145152161189212234261-50.00
  Retained Earnings-1.1%-289-286-270-247-182-212-176-148-123-144-74.90-15.74
  Additional Paid-In Capital15.0%4744124093931863733653613571673.000.00
Shares Outstanding31.4%59.0045.0044.0039.0035.0035.0032.0032.0018.0018.001.001.00
Float----97.00---77.00----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Cashflow From Operations-35.8%-20,710-15,254-17,583-11,031-26,841-17,387-20,557-43,051-8,340-745-7,2882,862-18,731--
  Share Based Compensation34.4%4,3203,2155,1793,6684,8843,8984,4496,996421-2,1863075722,450--
Cashflow From Investing-280.9%-18,49810,2286,571-22,255-99,393-1,858-4,266-2,7952,52022,614--371-219--
Cashflow From Financing230144.0%57,511-25.00-1713,5852,540-6.00249-72.00-149,107-1,708-682151,534--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PYXS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues$ 16,146 
Costs and operating expenses:  
Cost of revenues475 
Research and development13,029$ 11,901
General and administrative8,2479,053
Total costs and operating expenses21,75120,954
Loss from operations(5,605)(20,954)
Other income, net:  
Interest and investment income1,5501,673
Sublease income79938
Total other income, net2,3491,711
Net loss$ (3,256)$ (19,243)
Net loss per common share - basic$ (0.06)$ (0.54)
Net loss per common share - diluted$ (0.06)$ (0.54)
Weighted average shares of common stock outstanding - basic51,289,28435,351,671
Weighted average shares of common stock outstanding - diluted51,289,28435,351,671
Other comprehensive (loss) income:  
Net unrealized (loss) gain on marketable debt securities$ (123)$ 696
Other comprehensive (loss) income(123)696
Comprehensive loss(3,379)$ (18,547)
Royalty Revenues  
Revenues8,146 
Sale of Royalty Rights  
Revenues$ 8,000 

PYXS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 27,967$ 9,664
Marketable debt securities, short-term129,060109,634
Restricted cash1,4721,472
Accounts receivable8,000 
Prepaid expenses and other current assets5,8803,834
Total current assets172,379124,604
Property and equipment, net11,33311,872
Intangible assets, net23,73024,308
Operating lease right-of-use assets12,77812,942
Total assets220,220173,726
Current liabilities:  
Accounts payable2,2933,896
Accrued expenses and other current liabilities10,82812,971
Operating lease liabilities, current portion1,0201,232
Deferred revenues 7,660
Total current liabilities14,14125,759
Operating lease liabilities, net of current portion19,75920,099
Deferred tax liability, net2,1642,164
Total liabilities36,06448,022
Commitments and contingencies (Note 14)
Stockholders' equity:  
Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding
Common stock, $0.001 par value per share; 190,000,000 shares authorized; 58,803,126 and 44,754,853 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.5945
Additional paid-in capital473,638411,821
Accumulated other comprehensive (loss) income(60)63
Accumulated deficit(289,481)(286,225)
Total stockholders' equity184,156125,704
Total liabilities and stockholders' equity$ 220,220$ 173,726
PYXS
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://pyxisoncology.com
 INDUSTRYBiotechnology
 EMPLOYEES72

Pyxis Oncology, Inc. Frequently Asked Questions


What is the ticker symbol for Pyxis Oncology, Inc.? What does PYXS stand for in stocks?

PYXS is the stock ticker symbol of Pyxis Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pyxis Oncology, Inc. (PYXS)?

As of Thu Jul 11 2024, market cap of Pyxis Oncology, Inc. is 174.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PYXS stock?

You can check PYXS's fair value in chart for subscribers.

What is the fair value of PYXS stock?

You can check PYXS's fair value in chart for subscribers. The fair value of Pyxis Oncology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pyxis Oncology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PYXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pyxis Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether PYXS is over valued or under valued. Whether Pyxis Oncology, Inc. is cheap or expensive depends on the assumptions which impact Pyxis Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PYXS.

What is Pyxis Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 11 2024, PYXS's PE ratio (Price to Earnings) is -3.03 and Price to Sales (PS) ratio is 8.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PYXS PE ratio will change depending on the future growth rate expectations of investors.